Hannah G Juncker1,2, Sien J Mulleners1, Marit J van Gils3, Christianne J M de Groot4, Dasja Pajkrt1, Aniko Korosi2, Johannes B van Goudoever1, Britt J van Keulen1. 1. 332563 Amsterdam UMC, Vrije Universiteit, University of Amsterdam, Emma Children's Hospital, Amsterdam Reproduction & Development Research Institute, Department of Pediatrics, Amsterdam, the Netherlands. 2. Swammerdam Institute for Life Sciences - Center for Neuroscience, University of Amsterdam, Amsterdam, the Netherlands. 3. 26066 Amsterdam UMC, University of Amsterdam, Amsterdam Infection and Immunity Institute, Department of Medical Microbiology and Infection Prevention, Amsterdam, the Netherlands. 4. 120984709 Amsterdam UMC, Vrije Universiteit, Amsterdam Reproduction & Development Research Institute, Department of Obstetrics and Gynaecology, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being administered around the world; however, lactating women were excluded from SARS-CoV-2 vaccine trials. Therefore, knowledge about the effect of vaccination in this specific group is limited. This information is essential to empower lactating women to make a well-informed decision on their choice for vaccination. After natural infection, SARS-CoV-2 specific antibodies are present in human milk, which might offer protection for her newborn. The dynamics of these antibodies in human milk following vaccination remain to be elucidated. RESEARCH AIM: To determine the effect of vaccination with BNT162b2 on the levels of SARS-CoV-2 specific IgA in human milk. METHODS: In this prospective longitudinal study, we included lactating women who received the BNT162b2 vaccine. Human milk samples were collected prior to vaccination and 3, 5, 7, 9, 11, 13, and 15 days after both vaccine doses. Samples were analyzed using enzyme-linked immunosorbent assay against the spike protein of SARS-CoV-2. RESULTS: In total, 366 human milk samples from 26 lactating women were analyzed. A biphasic response was observed, with SARS-CoV-2 specific immunoglobulin A (IgA) starting to increase between day 5 and 7 after the first dose of the vaccine. After the second dose, an accelerated IgA antibody response was observed. CONCLUSION: After vaccination with the mRNA-based BNT162b2 vaccine, a SARS-CoV-2 specific antibody response was observed in human milk. The presence of SARS-CoV-2 specific IgA after vaccination is important as antibodies are transferred via human milk, and thereby might provide protection to infants against COVID-19.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being administered around the world; however, lactating women were excluded from SARS-CoV-2 vaccine trials. Therefore, knowledge about the effect of vaccination in this specific group is limited. This information is essential to empower lactating women to make a well-informed decision on their choice for vaccination. After natural infection, SARS-CoV-2 specific antibodies are present in human milk, which might offer protection for her newborn. The dynamics of these antibodies in human milk following vaccination remain to be elucidated. RESEARCH AIM: To determine the effect of vaccination with BNT162b2 on the levels of SARS-CoV-2 specific IgA in human milk. METHODS: In this prospective longitudinal study, we included lactating women who received the BNT162b2 vaccine. Human milk samples were collected prior to vaccination and 3, 5, 7, 9, 11, 13, and 15 days after both vaccine doses. Samples were analyzed using enzyme-linked immunosorbent assay against the spike protein of SARS-CoV-2. RESULTS: In total, 366 human milk samples from 26 lactating women were analyzed. A biphasic response was observed, with SARS-CoV-2 specific immunoglobulin A (IgA) starting to increase between day 5 and 7 after the first dose of the vaccine. After the second dose, an accelerated IgA antibody response was observed. CONCLUSION: After vaccination with the mRNA-based BNT162b2 vaccine, a SARS-CoV-2 specific antibody response was observed in human milk. The presence of SARS-CoV-2 specific IgA after vaccination is important as antibodies are transferred via human milk, and thereby might provide protection to infants against COVID-19.
Authors: Bridget E Young; Antti E Seppo; Nichole Diaz; Casey Rosen-Carole; Anna Nowak-Wegrzyn; Joseline M Cruz Vasquez; Rita Ferri-Huerta; Phuong Nguyen-Contant; Theresa Fitzgerald; Mark Y Sangster; David J Topham; Kirsi M Järvinen Journal: JAMA Pediatr Date: 2022-02-01 Impact factor: 16.193
Authors: Jiong Wang; Bridget E Young; Dongmei Li; Antti Seppo; Qian Zhou; Alexander Wiltse; Anna Nowak-Wegrzyn; Katherine Murphy; Kaili Widrick; Nicole Diaz; Joseline Cruz-Vasquez; Kirsi M Järvinen; Martin S Zand Journal: Vaccines (Basel) Date: 2022-06-20
Authors: Hannah G Juncker; Eliza J M Ruhé; Aniko Korosi; Johannes B van Goudoever; Marit J van Gils; Britt J van Keulen Journal: Front Nutr Date: 2022-06-30
Authors: Stephanie E Perez; Luis Diego Luna Centeno; Wesley A Cheng; Carolyn Jennifer Marentes Ruiz; Yesun Lee; Zion Congrave-Wilson; Rebecca L Powell; Lisa Stellwagen; Pia S Pannaraj Journal: Pediatrics Date: 2022-02-01 Impact factor: 9.703
Authors: Hannah G Juncker; Sien J Mulleners; Marit J van Gils; Tom P L Bijl; Christianne J M de Groot; Dasja Pajkrt; Aniko Korosi; Johannes B van Goudoever; Britt J van Keulen Journal: Vaccines (Basel) Date: 2021-12-14
Authors: L Ryan; Frans B Plötz; Agnes van den Hoogen; Jos M Latour; Marina Degtyareva; Maya Keuning; Claus Klingenberg; Irwin K M Reiss; Eric Giannoni; Charles Roehr; Christopher Gale; Eleanor J Molloy Journal: Pediatr Res Date: 2021-12-28 Impact factor: 3.953
Authors: Yarden Golan; Mary Prahl; Arianna G Cassidy; Caryl Gay; Alan H B Wu; Unurzul Jigmeddagva; Christine Y Lin; Veronica J Gonzalez; Emilia Basilio; Megan A Chidboy; Lakshmi Warrier; Sirirak Buarpung; Lin Li; Amy P Murtha; Ifeyinwa V Asiodu; Nadav Ahituv; Valerie J Flaherman; Stephanie L Gaw Journal: Front Immunol Date: 2021-11-03 Impact factor: 7.561